Abstract
Hepatosplenic T-cell non-Hodgkin's lymphoma (HSTCL) is a rare, aggressive form of NHL, with a median survival of approximately 8 months. We were able to successfully induce complete remission in a patient with α/β HSTCL who was refractory to multiple prior chemotherapy regimens, using the humanized anti-CD52 monoclonal antibody alemtuzumab (Campath®). Once disease was controlled, the patient was able to undergo allogeneic stem cell transplantation (SCT), which resulted in complete remission. Furthermore, upon relapse, we were able to re-induce complete clinical and molecular remission with donor lymphocyte infusions. At Day 655 (post-SCT), the patient remains in complete remission. These data suggest a potential role for alemtuzumab and allogeneic SCT in the treatment of T-cell NHL.
Original language | English (US) |
---|---|
Pages (from-to) | 1673-1675 |
Number of pages | 3 |
Journal | Leukemia and Lymphoma |
Volume | 45 |
Issue number | 8 |
DOIs | |
State | Published - Aug 2004 |
Keywords
- Alemtuzumab
- Allogeneic
- Non-Hodgkin's lymphoma
- T-cell
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research